Summary of the II Brazilian Guideline Update on Acute Heart Failure 2009/2011

Marcelo Westerlund Montero1,2, Sabrina Bernardez Pereira1, Alexandre Siciliano Colafranceschi1,9, Direceu Rodrigues de Almeida4, Evandro Mesquita Tinoco1, Ricardo Mouriilhe Rocha5, Lidia Ana Zytnyski Moura6, Álvaro Rêa-Neto7, Sandrigo Mangini8, Fabiana Goulart Marcondes Braga8, Deniison Campos Albuquerque3, Edson Stefani6, Eduardo Benchimol Saad9, Fábio Vilas-Boas10
Hospital Pró Cardíaco, RJ1; Santa Casa de Misericórdia, RJ2; Universidade Federal Fluminense, RJ3; Universidade Federal de São Paulo4; Universidade do Estado do Rio de Janeiro5; Pontifícia Universidade Católica do Paraná6; Universidade Federal do Paraná7; Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo8; Instituto Nacional de Cardiologia, RJ9; Hospital Espanhol, Bahia10

Abstract
In the past two years we observed several changes in the diagnostic and therapeutic approach of patients with acute heart failure (acute HF), which led us to the need of performing a summary update of the II Brazilian Guidelines on Acute Heart Failure 2009.

In the diagnostic evaluation, the diagnostic flowchart was simplified and the role of clinical assessment and echocardiography was enhanced. In the clinical-hemodynamic evaluation on admission, the hemodynamic echocardiography gained prominence as an aid to define this condition in patients with acute HF in the emergency room. In the prognostic evaluation, the role of biomarkers was better established and the criteria and prognostic value of the cardiorenal syndrome was better defined.

The therapeutic approach flowcharts were revised, and are now simpler and more objective. Among the advances in drug therapy, the safety and importance of the maintenance or introduction of beta-blockers in the admission treatment are highlighted. Anticoagulation, according to new evidence, gained a wider range of indications. The presentation hemodynamic models of acute pulmonary edema were well established, with their different therapeutic approaches, as well as new levels of indication and evidence. In the surgical treatment of acute HF, CABG, the approach to mechanical lesions and heart transplantation were reviewed and updated.

This update strengthens the II Brazilian Guidelines on Acute Heart Failure to keep it updated and refreshed. All clinical cardiologists who deal with patients with acute HF will find, in the guidelines and its summary, important tools to help them with the clinical practice for better diagnosis and treatment of their patients.

Keywords
Heart failure; diagnosis; prognosis; pulmonary edema; cardiac outpatient, low; shock, cardiogenic.

Introduction
Since the publication of the II Brazilian Guidelines on Acute Heart Failure in 2009, several advances have occurred regarding the diagnostic and prognostic capacity, as well as drug and nondrug therapy of acute HF. Due to this new information, the Department of Heart Failure of the Brazilian Society of Cardiology (Deic/SBC) carried out an executive summary update of this guideline.

The content of this summary update consists only of new information when compared to the 2009 guideline. What has not been published has been considered unaltered. Therefore, the reader should refer to the 2009 guideline to have access to the full content.

We added new indications for diagnosis and treatment of acute HF and reclassified several diagnostic and therapeutic methods, considering the new publications in the last two years.

Clinical diagnosis
The diagnostic evaluation of acute HF should be performed systematically within the first hours of admission at the emergency room. The diagnosis of acute HF is based on clinical signs and symptoms of pulmonary or systemic congestion, associated or not with the presence of low cardiac output supported by diagnostic tests. The presence of fatigue or hypovolemia should also be assessed. During the anamnesis and clinical examination, one must also establish whether the acute HF is of recent onset (New acute HF) or a case of acute chronic HF, as well as the likely causal and triggering factor of acute decompensated HF; the possible associated diseases and drugs that have been used. By analyzing the presence of congestion and low output, the clinical and hemodynamic evaluation is performed and, finally, the patient risk profile is assessed and the therapeutic targets to be achieved are defined.

- The use of systematic diagnostic evaluation is recommended, through Framingham or Boston criteria, for the diagnosis of acute HF.

Class of recommendation I, Level of evidence B

Ecocardiograma
Admission assessment through two-dimensional echocardiography is used for analysis of systolic and diastolic function of left and right ventricles, hemodynamic estimates, in addition to valve involvement assessment and to estimate the likely causal factor.

Class of recommendation I, Level of evidence B
Other non-invasive and invasive examinations

Cardiac magnetic resonance imaging
When using the late gadolinium enhancement technique as a contrast, one can obtain information on inflammation, infiltrative processes and areas of edema or fibrosis, being useful in the investigation of myocarditis, myocardial infarction scars, pericardial diseases, cardiomyopathies, infiltrative and storage diseases. Limitations include patients with pacemakers, ocular or intracranial metallic clips and patient intolerance.

For the investigation of myocarditis and etiology, as well as assessment of cardiac volumes, when the echocardiography is not conclusive.

*Class of recommendation I, Level of evidence B*

Pulmonary Function Tests
They can be useful to exclude lung diseases as the cause of dyspnea. Their use in acute HF, however, is limited, as the presence of congestion can influence results.

*Class of recommendation III, Level of evidence C*

Coronary angiography
It is indicated in cases of acute coronary syndrome as a cause of HF. The reperfusion strategy (percutaneous or surgical) must be considered in appropriate patients, being related to the improved prognosis1.

*Class of recommendation I, Level of evidence B*

Pulmonary artery catheter
The use of a pulmonary artery catheter is usually not necessary for the diagnosis of HF. It may be useful to differentiate cardiogenic from non-cardiogenic shock in complex patients or in the presence of associated lung disease.

*Class of recommendation IIb, Level of evidence B*

Clinical and hemodynamic evaluation of patients with acute HF

Hemodynamic echocardiogram
In the context of acute HF, the echocardiography can detect and define hemodynamic alterations, quantifying intracavitary pressures and guiding therapy in an equivalent way to invasive methods2,3.

- Hemodynamic assessment of acute HF through hemodynamic echocardiography.

*Class of recommendation I, Level of evidence B*

Transthoracic bioimpedance (TB)
Hemodynamic evaluation by TB in patients with acute HF is superior to clinical evaluation in the diagnosis of pulmonary congestion (PC) and low cardiac output, and the value of lung water > 18 was a strong predictor of BNP > 200 pg/mL in the diagnosis of PC4.
Markers of risk profile and prognosis in acute HF

Cardiac markers and echocardiography

- **BNP/N-proBNP**
  - Retrospective studies and data from international registries have shown that high levels during hospitalization and at hospital discharge of BNP (> 750 ng/dL) and its precursor NT-proBNP are independent predictors of mortality and rehospitalization.
  - **Class of recommendation IIa, Level of evidence B**

- **Troponins**
  - Retrospective studies and the ADHERE registry have identified that alterations in serum levels of troponin T and I > 0.01 mg/dL are independent predictors of poor in-hospital and after discharge prognosis.
  - **Class of recommendation IIa, Level of evidence B**

Ecocardiografía

In the setting of acute HF, echocardiography provides parameters that help in risk stratification, such as ejection fraction, left ventricular diameter, pulmonary pressure, filling pressures and cardiac output.

**Class of recommendation I, Level of evidence B**

Table 1 - Targets in the treatment of acute HF

<table>
<thead>
<tr>
<th>Early phase</th>
<th>Late phase</th>
<th>Laboratory</th>
<th>Hemodynamic</th>
<th>Metabolic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decrease signs and symptoms of congestion in 6 hours</td>
<td>Adequate oxygenation (SatO2 &gt; 90%)</td>
<td>Electrolytic normalization</td>
<td>Optimize cardiac output (by echocardiogram or bioimpedance)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maintain adequate diuresis: &gt; 0.5 mL/Kg/h</td>
<td>Prevent creatinine increase &gt; 0.3 mg/dL</td>
<td>(By echocardiogram or bioimpedance)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prevent SBP &lt; 90 mmHg</td>
<td>Decrease BNP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reverse hemodynamic disorder</td>
<td>Decrease troponin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Decrease CRP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Arterial lactate normalization</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SVO2 &gt; 70%</td>
</tr>
</tbody>
</table>

**Targets in the treatment of acute HF**

The treatment of acute HF should be aimed at patient optimization by reaching clinical, hemodynamic and metabolic targets shown in Table 1.

- Establish therapeutic targets to guide treatment of patients with acute HF.
  - **Class of recommendation I, Level of evidence C**

- **Chest Ultrasonography**
  - The chest ultrasonography allows the differential diagnosis of pulmonary congestion and chronic obstructive pulmonary disease by analyzing the B-lines of congestion (comet-tails), and A-lines in COPD. B-lines have a sensitivity of 97% and specificity of 93% for the diagnosis of pulmonary congestion.
  - Differential diagnosis of dyspnea in the emergency room by chest ultrasonography.
  - **Class of recommendation IIb, Level of evidence C**

Invasive monitoring

- **Placement of invasive blood pressure catheter (arterial line)**
  - To monitor the mean arterial pressure, usually through radial or femoral access:
    - Hemodynamic instability necessitating the use of vasopressor amines;
    - Necessity to collect frequent arterial blood gas samples;
    - Use of intravenous sodium nitroprusside for clinical compensation.
  - **Class of recommendation IIa, Level of evidence C**

- **Placement of central venous catheter (venous line)**
  - Need for vasopressors (especially norepinephrine);
  - To monitor central venous oxygen saturation (SVO2) when indicated;
  - To monitor central venous pressure.
  - **Class of recommendation IIa, Level of evidence C**

- **Placement of a pulmonary artery catheter (Swan-Ganz)**
  - To evaluate the hemodynamic routine: the use of pulmonary artery catheter in the assessment of all patients with acute HF should not be performed.
  - **Class of recommendation III, Level of evidence C**

**Markers of risk profile and prognosis in acute HF**

**Cardiac markers and echocardiography**

**BNP/N-proBNP**

- Retrospective studies and data from international registries have shown that high levels during hospitalization and at hospital discharge of BNP (> 750 ng/dL) and its precursor NT-proBNP are independent predictors of mortality and rehospitalization.
  - **Class of recommendation IIa, Level of evidence B**

**Troponins**

- Retrospective studies and the ADHERE registry have identified that alterations in serum levels of troponin T and I > 0.01 mg/dL are independent predictors of poor in-hospital and after discharge prognosis.
  - **Class of recommendation IIa, Level of evidence B**

**Ecocardiografía**

- In the setting of acute HF, echocardiography provides parameters that help in risk stratification, such as ejection fraction, left ventricular diameter, pulmonary pressure, filling pressures and cardiac output.
  - **Class of recommendation I, Level of evidence B**

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Targets in the treatment of acute HF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early phase</td>
<td>Adequate oxygenation (SatO2 &gt; 90%)</td>
</tr>
<tr>
<td></td>
<td>Maintain adequate diuresis: &gt; 0.5 mL/Kg/h</td>
</tr>
<tr>
<td></td>
<td>Prevent SBP &lt; 90 mmHg</td>
</tr>
<tr>
<td></td>
<td>Reverse hemodynamic disorder</td>
</tr>
<tr>
<td>Late phase:</td>
<td>Prevent rehospitalization</td>
</tr>
<tr>
<td></td>
<td>Decrease mortality</td>
</tr>
<tr>
<td></td>
<td>Decrease hospital stay duration</td>
</tr>
<tr>
<td>Laboratory:</td>
<td>Electrolytic normalization</td>
</tr>
<tr>
<td></td>
<td>Prevent creatinine increase &gt; 0.3 mg/dL</td>
</tr>
<tr>
<td></td>
<td>Decrease BNP</td>
</tr>
<tr>
<td></td>
<td>Decrease troponin</td>
</tr>
<tr>
<td></td>
<td>Decrease CRP</td>
</tr>
<tr>
<td>Hemodynamic:</td>
<td>Decrease filling pressures (by echocardiogram or bioimpedance)</td>
</tr>
<tr>
<td></td>
<td>Optimize cardiac output (By echocardiogram or bioimpedance)</td>
</tr>
<tr>
<td>Metabolic:</td>
<td>Arterial lactate normalization</td>
</tr>
<tr>
<td></td>
<td>SVO2 &gt; 70%</td>
</tr>
</tbody>
</table>
Cardiorenal syndrome

When the acute kidney injury results from acute cardiac dysfunction, it is called cardiorenal syndrome type 1 and is present in 30% to 50% of patients hospitalized with acute HF. The criterion for diagnosis is the increase in serum creatinine ≥ 0.3 mg/dL or an increase > 50% of the hospital admission one. Other biomarkers such as NGAL and Cystatin-C have a greater capacity for early detection of kidney injury in the context of acute HF than creatinine and urea.

- Monitoring of renal function with NGAL or Cystatin C to detect cardiorenal syndrome.

Class of recommendation IIb, Level of evidence B

Risk profile

Other scores of mortality

In addition to the ADHERE score, two other in-hospital acute HF mortality risk scores have been published more recently: OPTIMIZE and GWTG-HF.

- Use of risk scores for prognostic risk stratification of patients with acute HF at hospital admission.

Class of recommendation I, Level of evidence A

Acute HF Treatment

The rationale of the therapeutic approach in acute HF is established from the combination of three main factors: the development model of acute HF with causal factor + BP + clinical and hemodynamic assessment. This rationale establishes the flow charts of the therapeutic approach (figures 2, 3, 4):

Clinical Treatment

Intravenous medications in the acute phase and during hospitalization

Diuretics

Oral and intravenous diuretics in acute HF: dose and dose interval (table 2).

Use of furosemide at 4-hour intervals or continuous infusion in cases of unsatisfactory response or severe systemic congestion. Continuous infusion with an initial dose of 10 mg/h, with 10-20 mg increases, preceded by infusion of 10 mg in bolus.

Class of recommendation I, Level of evidence B

The use of hypertonic saline solution associated with furosemide (NaCl 4.6% to 7.5%, 100 to 150 ml, infused 20-30 minutes) may be considered for hyponatremic patients refractory or not to the initial treatment.

Class of recommendation IIa, Level of evidence B

Intravenous vasodilators

- Nesiritide

Recently, a large randomized trial (ASCEND-HF) showed that nesiritide does not reduce mortality in patients with acute HF, improving dyspnea, with no increase in serious adverse events, which limits its routine use due to the current cost of the medication, even though it is the most studied vasodilator.

- For the treatment of acute HF in patients without hypotension.

Class of recommendation IIb, Level of evidence A

Figure 2 - Stratification of mortality risk of patients with acute HF according to the epidemiological data of the ADHERE registry.
Fig. 3 - Flowchart of therapeutic rationale of new acute HF.

Fig. 4 - Flowchart of therapeutic rationale of acute chronic HF.
Volume replacement

Dynamic evaluation methods of cardiovascular responsiveness to volume

- Spontaneous ventilation

  The inspiratory variation of CVP $\geq 1$ mmHg\(^{15}\), the increase in aortic flow and/or blood pressure and/or CVP after passive elevation of the lower limbs (45\(^{\circ}\))\(^{16,17}\) and increased pulse pressure variation through the Valsalva maneuver have high accuracy in the identification of responsive patients.

  **Class of recommendation IIa, Level of evidence C**

- Mechanical ventilation

  Inspiratory variation of CVP, systolic volume, aortic flow, arterial pulse pressure, pulse plethysmography and vena cava collapse index allow the reliable assessment of cardiovascular responsiveness in mechanically ventilated patients without cardiac arrhythmias\(^{18,19}\).

  **Class of recommendation IIa, Level of evidence C**

Oral medications in the acute phase and during hospitalization

**Digitalis**

The use of digitalis in acute HF has not been tested in randomized clinical trials. Digitalis has been recommended as an aid to beta-blockers, or even before its introduction in the control of HR in patients with decompensated HF with systolic dysfunction, atrial fibrillation and ventricular response $> 80$ bpm. Its use should be avoided in patients with acute coronary artery disease. Dosage: 0.4 mg in 100 ml of saline solution, infused over 30 minutes.

  **Class of recommendation IIa, Level of evidence C**

**Beta-blockers**

Beta-blockers (BB) should be introduced at hospital admission in patients with acute HF who were not previously using it, or maintained in those with previous use, as clinical benefits have been demonstrated in reducing in-hospital and outpatient mortality, with lower readmission rates, with no clinical or hemodynamic worsening of patients and led to higher rate of prescription at discharge\(^{20-22}\).

When inotropic support is necessary, levosimendan and phosphodiesterase inhibitor (Milrinone)\(^{23,24}\), as they do not suffer BB antagonism, are more suitable. Dobutamine shows partial reduction of its effects and may have deleterious hemodynamic action in patients using carvedilol\(^{25}\).

BB should be started at low doses and can be adjusted every 3-5 days; the development of hypotension, bradycardia, worsening of pulmonary congestion, low cardiac output or impaired renal function must be verified. In these situations, one must return to the previous dose and stop the progression of BB. The presence of clinical conditions such as anemia, hypovolemia, excessive vasodilator dose and inflammatory states predisposes to the development of hypotension with the use of BB.

BB with proven benefits in acute HF are bisoprolol, carvedilol and metoprolol succinate. The others have not been used in clinical studies in patients with acute HF.

**Indications of the use of beta-blockers in acute HF**

- Start or maintain the BB in patients with no evidence of hypotension or low cardiac output.

  **Class of recommendation I, Level of evidence A**

- Reduce the dose of BB by 50% or withdraw it at the admission in patients with signs of low cardiac output without arterial hypotension.

  **Class of recommendation I, Level of evidence B**

- Reduce the dose of BB by 50% in patients with hypotension without low cardiac output.

  **Class of recommendation IIa, Level of evidence C**

- Withdraw BB in patients with cardiogenic or septic shock, critical aortic stenosis, decompensated asthma, advanced atrioventricular block.

  **Class of recommendation I, Level of evidence C**

---

**Table 2 - Classes, mechanism of action, initial and maximum dose of diuretics in acute HF**

<table>
<thead>
<tr>
<th>Diuretics</th>
<th>Initial dose (mg)</th>
<th>Maximum dose (mg)</th>
<th>Interval (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loop Diuretics:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Furosemide</td>
<td>20</td>
<td>240</td>
<td>4/6;6/12/12</td>
</tr>
<tr>
<td>• Bumetanide</td>
<td>0.5 – 2.0</td>
<td>10</td>
<td>6/6</td>
</tr>
<tr>
<td>Thiazide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Hydrochlorothiazide</td>
<td>25</td>
<td>100</td>
<td>24/24 - 12/12</td>
</tr>
<tr>
<td>• Chlorothalidone</td>
<td>12.5</td>
<td>50</td>
<td>24/24</td>
</tr>
<tr>
<td>• Indapamide</td>
<td>2.5</td>
<td>5.0</td>
<td>24/24</td>
</tr>
<tr>
<td>Potassium-sparing diuretics:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Spironolactone</td>
<td>25</td>
<td>50</td>
<td>24/24</td>
</tr>
<tr>
<td>• Amiloride</td>
<td>2.5</td>
<td>20</td>
<td>24/24</td>
</tr>
<tr>
<td>• Triamterene</td>
<td>25</td>
<td>100</td>
<td>24/24</td>
</tr>
</tbody>
</table>
ACE Inhibitors/ARBs

In the presence of clinical situations of hypovolemia, hyponatremia, anemia, inflammatory states, or sepsis due to the potential development of hypotension or worsening of renal function, the introduction of ACE inhibitors or ARBs should be postponed for the correction of these disorders.\cite{26, 27}

In patients with LV dysfunction after MI, there is enough evidence to suggest the early use of ACE inhibitors in all patients without contraindications.\cite{28-30}

ARBs have been extensively tested against ACE inhibitors, but there is no evidence of superiority of one agent over another.\cite{31, 32} Their main indication is for patients who cannot tolerate ACE inhibitors because of coughing.

**Indications and levels of evidence of ACEI and ARB use in acute HF**

- Start or maintenance of ACE inhibitors in the absence of signs of low output or symptomatic arterial hypotension.
  
  **Class of recommendation I, Level of evidence A**

- Start or maintenance of ARB in the absence of signs of low output or symptomatic hypotension.
  
  **Class of recommendation I, Level of evidence B**

**Spironolactone**

- Use of spironolactone in HF FC III and IV with EF < 35% after the use of intravenous diuretics.
  
  **Class of recommendation I, Level of evidence B**

**Full and prophylactic anticoagulation in acute HF**

- Use of anticoagulation with LMWH or UFH in patients with decompensated HF in the presence of atrial fibrillation, identification of intracavitary thrombus, mechanical valve prosthesis, with or without ventricular dysfunction.\cite{33, 34}
  
  **Class of recommendation I, Level of evidence A**

- Use of full anticoagulation with LMWH or UFH associated with antiaggregant agents in patients with decompensated HF with acute coronary syndrome.\cite{35}
  
  **Class of recommendation I, Level of evidence A**

- Use of prophylactic anticoagulation with LMWH or UFH in patients with decompensated HF, peripartum cardiomyopathy, myocardial noncompaction.$^\text{36}$
  
  **Class of recommendation I, Level of evidence C**

- Prophylaxis of DVT, with low-dose unfractionated heparin or low molecular weight heparin, during confinement in bed.\cite{37}
  
  **Class of recommendation I, Level of evidence B**

- In patients with kidney dysfunction (creatinine clearance < 30 mL/min), avoid the use of LMWH, the preferential use of UFH is recommended.
  
  **Class of recommendation I, Level of evidence B**

- Use of full anticoagulation with LMWH or UFH in patients with severe ventricular dysfunction.
  
  **Class of recommendation IIb, Level of evidence C**

**Specific situations**

**Acute Pulmonary Edema (APE)**

APE has two distinct hemodynamic models of volume distribution:

1) Pulmonary congestion with peripheral hypovolemia observed in pictures of new acute HF in patients with no prior HF and normal blood volume. Treatment aims to redistribute the volume of pulmonary circulation into the peripheral circulation by the action of arterial vasodilators associated with ventilatory support with noninvasive positive pressure. It is not intended as priority the use of large doses of diuretics, as they can induce low cardiac output by reducing the right ventricular preload.\cite{38}

- Restricted use of diuretics in APE for new acute HF:
  
  **Class of recommendation IIa, Level of evidence B**

2) Pulmonary and systemic congestion, observed in patients with aggravated acute chronic HF. Treatment priority is the reduction of blood volume through the large-scale use of diuretics associated with vasodilators for the improvement of ventricular function and sometimes, inotropic agents, in the presence of low cardiac output.

- Unrestricted use of intravenous diuretics in APE due to acute chronic HF:
  
  **Class of recommendation IIa, Level of evidence B**

- The noninvasive ventilatory support with positive pressure is associated with reduced respiratory load and pulmonary congestion, with consequent improvement in dyspnea and decreased need for orotracheal intubation and mechanical ventilatory support.

- Noninvasive ventilatory support with positive pressure on admission of patients with no evidence of respiratory failure:
  
  **Class of recommendation I, Level of evidence B**

- Orotracheal intubation is indicated in the presence of respiratory failure (invasive mechanical ventilatory support).
  
  **Class of recommendation I, Level of evidence B**

- The use of opioids has shown benefits in reducing adrenergic activity with a consequent reduction in systemic vascular resistance and respiratory load. One should be cautious in situations of relative hypovolemia as in new acute HF.\cite{39}
  
  **Class of recommendation I, Level of evidence B**

**Invasive treatment of acute HF**

**Myocardial Revascularization (MR)**

**Recommendations for MR**

- Early, percutaneous or surgical MR is indicated in the presence of acute HF with ongoing ischemia.\cite{40}
  
  **Class of recommendation I, Level of evidence B**
- Early MR is indicated in patients with AMI who develop cardiogenic shock in the presence of critical coronary lesion that can be treated.\(^{41}\)

**Class of recommendation I, Level of evidence B**

Early MR in patients with left ventricular dysfunction and hemodynamic instability, with significant mass of viable, non-contractile myocardium and favorable anatomy.\(^{42}\)

**Class of recommendation IIa, Level of evidence B**

Recommendations for the management of the patient with mechanical complications of AMI

- The surgical treatment of mechanical complications of acute myocardial infarction should be performed early to prevent hemodynamic deterioration, despite the use of intraventricular artery.\(^{1}\)

**Class of recommendation I, Level of evidence B**

- The implant of mechanical circulatory support is indicated in patients with hemodynamic instability despite inotropic support.\(^{44}\)

**Class of recommendation IIa, Level of evidence C**

- MR associated with left ventricular reconstruction can be recommended in patients with HF and fibrosis in the region corresponding to the territory of the anterior interventricular artery.\(^{45}\)

**Class of recommendation IIb, Level of evidence B**

- The routine use of assistance with a centrifugal pump is not recommended.\(^{46}\)

**Class of recommendation III, Level of evidence B**

### References


14. Hernandez AF. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)—Nesiritide or placebo for improved symptoms and outcomes in acute decompensated Late-Breaking Clinical Trials I: In: Scientific Sessions—American Heart Association; November 14-17, 2010; Chicago, IL.


